The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.
ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early ...
Dr. Lakshmi Nayak, director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute, explained in an interview with ...
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
(Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, ...
FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higher Trial ...
In the rapidly moving field, questions remain regarding long-term safety, durability of remission, and the FDA’s approach to ...
"The FDA approval of Optune Pax marks the first new treatment in decades for people living with locally advanced pancreatic cancer," said Frank Leonard, CEO of Novocure. "Optune Pax is a fundamentally ...
During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.
ImmunityBio launched the ResQ215B Phase 2 trial of a chemotherapy free, outpatient immunotherapy regimen for indolent B cell non Hodgkin lymphoma. The trial combines CAR NK cell therapy with the ...
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results